Clinical significance of serum vascular endothelial growth factor, endostatin, and leptin levels in children with lymphoma

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1272-1277

  Okur, Fatma Visal ^a   Karadeniz, Ceyda ^a   Buyukpamukcu, Munevver ^b   Oguz, Aynur ^a   Yucel, Aysegul ^a   Cinaz, Peyami ^a   Emir, Suna ^c   Varan, Ali ^b  

^a GAZI UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Hodgkin's disease; Non Hodgkins lymphoma; Pediatric oncology

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ENDOSTATIN; LEPTIN; PREDNISONE; PROCARBAZINE; VASCULOTROPIN; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNORADIOMETRIC ASSAY; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD;

ANGIOGENESIS INHIBITORS; CHILD; DISEASE-FREE SURVIVAL; ENDOSTATINS; FEMALE; HODGKIN DISEASE; HUMANS; LEPTIN; LYMPHOMA, NON-HODGKIN; MALE; PROGNOSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78049291026     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22722     Document Type: Article

References (51)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Pavlakovic H, Von Schutz V, Rossler J, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001; 92: 756-760.
3. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994; 4: 207-218.
4. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-239.
5. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
6. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 504-509.
7. de Bont ES, Fidler V, Meeuwsen T, et al. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002; 8: 2856-2861.
8. Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238-243.
9. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003; 12: 167-171.
10. Jorgensen JM, Sorensen FB, Bendix K, et al. Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584-595.
11. Salven P, Manpaa H, Orpana A, et al. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-651.
12. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167-3172.
13. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677-683.
14. Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma: A morphometric approach in 286 patients with prognostic implications. Leukemia 2005; 19: 894-900.
15. Rueda A, Olmos D, Villareal V, et al. Elevated vascular endothelial growth factor pretreatment levels are correlated with the tumor burden in Hodgkin lymphoma and continue to be elevated in prolonged complete remission. Clin Lymphoma Myeloma 2007; 7: 400-405.
16. Citak EC, Oguz A, Karadeniz C, et al. Role of gelatinases (MMP-2 and MMP-9), TIMP-1, vascular endothelial growth factor (VEGF), and microvessel density on the clinicopathological behavior of childhood non-Hodgkin lymphoma. Pediatr Hematol Oncol 2008; 25: 55-66.
17. Citak EC, Oguz A, Karadeniz C, et al. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma. Pathol Res Pract 2008; 204: 89-96.
18. El-Houseini ME, Abdel-Azim SA, El-Desouky GI, et al. Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Natl Cancer Inst 2004; 16: 57-61.
19. Tabone MD, Landman-Parker J, Arcil B, et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001; 7: 538-543.
20. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225.
21. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2: 821-826.
22. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-1686.
23. Somasundar P, McFadden DW, Hileman SM, et al. Leptin is a growth factor in cancer. J Surg Res 2004; 116: 337-349.
24. Iversen PO, Drevon CA, Reseland JE. Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis. Blood 2002; 100: 4123-4128.
25. Wex H, Ponelis E, Wex T, et al. Plasma leptin and leptin receptor expression in childhood acute lymphoblastic leukemia. Int J Hematol 2002; 76: 446-452.
26. Coskun U, Gunel N, Toruner FB, et al. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 2003; 50: 41-46.
27. Lebrecht A, Ludwig E, Huber A, et al. Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol 2002; 85: 32-35.
28. Stattin P, Soderberg S, Hallmans G, et al. Leptin is associated with increased prostate cancer risk: A nested case-referent study. J Clin Endocrinol Metab 2001; 86: 1341-1345.
29. Bruserud O, Huang TS, Glenjen N, et al. Leptin in human acute myelogenous leukemia: Studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica 2002; 87: 584-595.
30. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003; 97: 2767-2775.
31. Feldman AL, Alexander HR, Jr., Yang JC, et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002; 95: 1637-1643.
32. Feldman AL, Pak H, Yang JC, et al. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001; 91: 1525-1529.
33. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
34. Giles FJ, Vose JM, Do KA, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res 2004; 28: 595-604.
35. Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients. Blood 2000; 96: 3712-3718.
36. Ribatti D, Vacca A, Nico B, et al. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56: 45-53.
37. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999; 79: 965-970.
38. Mainou-Fowler T, Angus B, Miller S, et al. Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PdEGF) in classical Hodgkin lymphoma (HL). Leuk Lymphoma 2006; 47: 223-230.
39. Mizia-Malarz A, Sobol G, Janowska J, et al. Prognostic value of proangiogenic cytokines in children with lymphomas. Pediatr Blood Cancer 2009; 53: 1195-1199.
40. Banks RE, Forbes MA, Kinsey SE, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-964.
41. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
42. Dhar DK, Ono T, Yamanoi A, et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 2002; 95: 2188-2195.
43. Gaja A, Chury Z, Pecen L, et al. Bone marrow and peripheral blood leptin levels in lymphoproliferative diseases-Relation to the bone marrow fat and infiltration. Neoplasma 2000; 47: 307-312.
44. Nishiyama M, Makino S, Suemaru S, et al. Glucocorticoid effects on the diurnal rhythm of circulating leptin levels. Horm Res 2000; 54: 69-73.
45. Collins S, Kuhn CM, Petro AE, et al. Role of leptin in fat regulation. Nature 1996; 380: 677.
46. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92: 1684-1688.
47. Laharrague P, Truel N, Fontanilles AM, et al. Regulation by cytokines of leptin expression in human bone marrow adipocytes. Horm Metab Res 2000; 32: 381-385.
48. Woessmann W, Seidemann K, Mann G, et al. The impact of methotrexate administration schedule and dose in the treatment of children and adolescent with B-cell neoplasms. Blood 2005; 105: 948-958.
49. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local therapy provides a 90% even-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 2000; 95: 416-421.
50. Patte C, Auperin A, Michon J, et al. The SFOP LMB89 protocol: Highly effective multi-agent chemotherapy tailored to tumor burden and initial response in 561 unselected children with B-cell lymphoma and L3 leukemia. Blood 2001; 97: 3370-3379
51. Jabbour E, Koscielny S, Sebban C, et al. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 2006; 20: 814-819.